Laboratory for Rehabilitation Neuroscience
Gainesville, Florida, 32611, United States
NCT Number: NCT03456687
The purpose of this research study is to investigate how the brain and motor behavior changes Parkinson's Disease (PD) over time in response to Exenatide. In previous clinical trials, PD patients have experienced symptomatic improvement on Exenatide and literature suggests it may help slow the progression of Parkinson's. Both will be evaluated in this study.
Looking for future studies?
Notify Me40 year–77 year
All sexes
Interventional
Phase 1
Gainesville, Florida, 32611, United States
Participants will receive baseline testing to confirm a diagnosis of Parkinson's Disease and to determine eligibility in the research study. All of the participants in this study will receive the study drug (Exenatide). The study drug will be provided at the end of the first visit, and participants will be administered the drug once per week for the duration of the study (1 year).
During the research study the following test may occur: (1) questionnaires about quality of life and depression; (2) tests to measure strength and motor function; (3) tests to measure cognition; (4) orientation session to learn a precision gripping task; (5) functional MRI scan of the brain; (6) structural MRI scan of the brain.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Exenatide will be administered through a subcutaneous injection once per week for the duration of the study (1 year).
Other names: Bydureon, Glucagon-like peptide-1 receptor agonist
Time frame: Baseline and one-year
12-month study in PD to watch the effect of Exenatide on the progressive increase of free-water accumulation in the substantia nigra.
Time frame: Baseline and one-year
12-month study in PD to watch the effect of Exenatide on BOLD signal in the posterior putamen.
Time frame: Baseline and one-year
12-month study in PD to watch the effect of Exenatide on BOLD signal in M1.
Time frame: Baseline and one-year
12-month study in PD to watch the effect of Exenatide on BOLD signal in the SMA.
University of Florida
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03648905
Autonomic Failure, Autonomic Nervous System Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT01621581
Basal Ganglia Diseases, Brain Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT05699460
Autonomic Nervous System Diseases, Basal Ganglia Diseases
Irvine, California, United States
View Trial DetailsNCT07720869
Basal Ganglia Diseases, Brain Diseases
Baton Rouge, Louisiana, United States
View Trial Details